Daewoong Pharmaceuticals, a leading Korean pharmaceutical company, announced its successful participation in the 16th International Master Course on Aging Science 2023 (IMCAS ASIA) held in Bangkok, Thailand from June 9th to 11th. The company's engagement at the conference aimed to enhance its global market network and highlight the exceptional qualities of its botulinum toxin product, Nabota.

IMCAS ASIA is renowned as one of the world's premier conferences for aesthetic plastic surgery, attracting 2,200 beauty and plastic surgery professionals and 85 sponsors. Daewoong Pharmaceuticals played an active role by hosting a dedicated booth for Nabota and organizing a Nabota master class. The company's booth, the largest among major Korean botulinum toxin manufacturers, garnered attention from professionals in the beauty surgery field, both domestically and internationally.

The Nabota master class, focused on the "Nabota Full Face Procedure for MZ Generation," targeted the latest beauty trends. Approximately 150 Asian beauty and plastic surgery professionals attended the class, reflecting the proactive approach of the MZ generation in seeking botulinum toxin treatments to maintain optimal skin condition for as long as possible.

The conference also featured sessions dedicated to sharing anatomical theories relevant to the Nabota procedure. Dr. Seung-Ho Han from Ewha Woman’s University School of Medicine delivered a lecture on "Facial Anatomy for Nabota Procedure," while Dr. Sung-Min Roh, the director of Yonsei Pastel Dermatology, discussed "Global Clinical Research on Nabota and Analysis of the Millennial Generation."

A highlight of the event was the live procedural demonstration presented by Dr. Chatchawan Srichayanurak, director of the TC Clinic, a prominent player in the Thai aesthetic plastic surgery market. Dr. Srichayanurak showcased the "Full Face Nabota Procedure," specifically tailored for MZ generation patients.

Daewoong Pharmaceuticals recognized Thailand as an important market with an estimated value of approximately 50 billion KRW (around 50 million USD) for botulinum toxin, and it is renowned for its aesthetic plastic surgery services in Southeast Asia.

According to Vice President Seong-Su Park, "Our participation in the global aesthetic plastic surgery conference provided us with an excellent opportunity to showcase the strengths of Nabota and educate professionals about the differentiated procedures tailored to the MZ generation, aligning with the latest trends in toxin treatments. With Nabota on the verge of acquiring the world's first indication for square jaw reduction, Daewoong Pharmaceuticals plans to leverage its global network to disseminate advanced techniques, expand evidence-based medical marketing, and enhance its aesthetic pipeline. Our aim is to establish ourselves as a prominent global aesthetic brand."

Daewoong Pharmaceuticals' self-developed and manufactured botulinum toxin product, Nabota, holds the distinction of being the only product in South Korea and Asia to receive FDA approval. As of June, Nabota has obtained product approvals in approximately 63 countries and has signed export contracts with over 80 countries. The company attributes Nabota's growing market share worldwide to its exceptional quality and high-purity botulinum toxin formulation.